These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 15769474)

  • 1. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis.
    Foss TR; Kelker MS; Wiseman RL; Wilson IA; Kelly JW
    J Mol Biol; 2005 Apr; 347(4):841-54. PubMed ID: 15769474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pathway by which the tetrameric protein transthyretin dissociates.
    Foss TR; Wiseman RL; Kelly JW
    Biochemistry; 2005 Nov; 44(47):15525-33. PubMed ID: 16300401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic stabilization of an oligomeric protein by a single ligand binding event.
    Wiseman RL; Johnson SM; Kelker MS; Foss T; Wilson IA; Kelly JW
    J Am Chem Soc; 2005 Apr; 127(15):5540-51. PubMed ID: 15826192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis.
    Wiseman RL; Green NS; Kelly JW
    Biochemistry; 2005 Jun; 44(25):9265-74. PubMed ID: 15966751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
    Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
    J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
    Sekijima Y; Dendle MA; Kelly JW
    Amyloid; 2006 Dec; 13(4):236-49. PubMed ID: 17107884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.
    Johnson SM; Wiseman RL; Sekijima Y; Green NS; Adamski-Werner SL; Kelly JW
    Acc Chem Res; 2005 Dec; 38(12):911-21. PubMed ID: 16359163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state.
    Petrassi HM; Johnson SM; Purkey HE; Chiang KP; Walkup T; Jiang X; Powers ET; Kelly JW
    J Am Chem Soc; 2005 May; 127(18):6662-71. PubMed ID: 15869287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
    Sekijima Y; Dendle MT; Wiseman RL; White JT; D'Haeze W; Kelly JW
    Amyloid; 2006 Jun; 13(2):57-66. PubMed ID: 16911959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers.
    Lai Z; McCulloch J; Lashuel HA; Kelly JW
    Biochemistry; 1997 Aug; 36(33):10230-9. PubMed ID: 9254621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation.
    Johnson SM; Petrassi HM; Palaninathan SK; Mohamedmohaideen NN; Purkey HE; Nichols C; Chiang KP; Walkup T; Sacchettini JC; Sharpless KB; Kelly JW
    J Med Chem; 2005 Mar; 48(5):1576-87. PubMed ID: 15743199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insight into pH-induced conformational changes within the native human transthyretin tetramer.
    Palaninathan SK; Mohamedmohaideen NN; Snee WC; Kelly JW; Sacchettini JC
    J Mol Biol; 2008 Oct; 382(5):1157-67. PubMed ID: 18662699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
    Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
    FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis.
    Adamski-Werner SL; Palaninathan SK; Sacchettini JC; Kelly JW
    J Med Chem; 2004 Jan; 47(2):355-74. PubMed ID: 14711308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization.
    Hurshman AR; White JT; Powers ET; Kelly JW
    Biochemistry; 2004 Jun; 43(23):7365-81. PubMed ID: 15182180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface.
    Liu K; Cho HS; Hoyt DW; Nguyen TN; Olds P; Kelly JW; Wemmer DE
    J Mol Biol; 2000 Nov; 303(4):555-65. PubMed ID: 11054291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention of misfolded mutant transthyretin by the chaperone BiP/GRP78 mitigates amyloidogenesis.
    Sörgjerd K; Ghafouri B; Jonsson BH; Kelly JW; Blond SY; Hammarström P
    J Mol Biol; 2006 Feb; 356(2):469-82. PubMed ID: 16376939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
    Lai Z; Colón W; Kelly JW
    Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
    Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
    J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of transthyretin amyloid disease by changing protein misfolding energetics.
    Hammarström P; Wiseman RL; Powers ET; Kelly JW
    Science; 2003 Jan; 299(5607):713-6. PubMed ID: 12560553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.